{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:40:32Z","timestamp":1790095232786,"version":"4.0.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) help manage type 2 diabetes (T2DM) and may have efficacy in steatotic liver disease. Objective: To determine the prevalence and clinical impact of GLP-1 RA use in patients with T2DM and liver disease. Methods: This was a retrospective study of adult patients with T2DM and nonalcoholic fatty liver disease (NAFLD), nonalcoholic fatty liver (NAFL), or nonalcoholic steatohepatitis (NASH) between 1\/1\/21-12\/31\/21. Patients with hepatitis B or C, or on pioglitazone were excluded. Eligible patients treated with a GLP-1 RA were compared to controls. The primary outcome was change in Fibrosis-4 (FIB-4) score, with NAFLD Fibrosis Score (NFS) as a secondary outcome. Follow-up scores were calculated from labs within 3 to 15 months after baseline. Results: Of 242 eligible patients, 79 patients (32.6%) were treated with a GLP-1 RA. At baseline, FIB-4 score was lower and NFS was higher in the GLP-1 RA group vs controls (1.80 vs 2.33; P = .101, .36 vs \u2212.47, P &lt; .001; respectively). At follow up, FIB-4 score decreased to 1.77 in the GLP-1 RA group and increased to 2.71 in controls (P = .045). Follow up NFS was stable in the GLP-1 RA group and increased in the control group (.36 vs \u2212.43; P = .308). Conclusion: Patients treated with GLP-1 RAs had less evidence of liver fibrosis progression compared to no treatment, although the differences were small. These results suggest that treatment with GLP-1 RAs may have clinical impact on slowing liver fibrosis, however results should be confirmed in a larger, more diverse sample.<\/jats:p>","DOI":"10.1177\/08971900241253661","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:23Z","timestamp":1715212823000},"page":"1297-1302","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of GLP-1 Receptor Agonist Use in Patients With Steatotic Liver Disease and Type 2 Diabetes: A Retrospective Cohort Study"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-8155","authenticated-orcid":false,"given":"Marci","family":"Wood","sequence":"first","affiliation":[{"name":"The University of Vermont Medical Center, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-4961","authenticated-orcid":false,"given":"Amanda G.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Medicine Quality Program, University of Vermont Larner College of Medicine, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Khan","sequence":"additional","affiliation":[{"name":"The University of Vermont Medical Center, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juvena R.","family":"Hitt","sequence":"additional","affiliation":[{"name":"Department of Medicine Quality Program, University of Vermont Larner College of Medicine, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Davis","sequence":"additional","affiliation":[{"name":"Ambulatory Clinical Pharmacist- Endocrinology, Yale New Haven Hospital, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela S.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Harvard Medical School, Boston, Beth Israel Deaconess Medical Center, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Osteoporosis, The University of Vermont Larner College of Medicine, Burlington, VT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"bibr1-08971900241253661","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073"},{"key":"bibr2-08971900241253661","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"bibr3-08971900241253661","first-page":"8936865","volume":"2021","author":"Rezaei S","year":"2021","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"bibr4-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"bibr5-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"bibr6-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.049"},{"key":"bibr7-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"bibr8-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669"},{"key":"bibr9-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"bibr10-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21496"},{"key":"bibr11-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520"},{"key":"bibr12-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"bibr13-08971900241253661","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S004"},{"key":"bibr14-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.031"},{"key":"bibr15-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29113"},{"key":"bibr16-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14669"},{"key":"bibr17-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04361-x"},{"key":"bibr18-08971900241253661","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802415"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241253661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241253661","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241253661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:33:29Z","timestamp":1777509209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241253661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/08971900241253661"],"URL":"https:\/\/doi.org\/10.1177\/08971900241253661","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}